acrymount mounting medium (Fisher Scientific)
90
Structured Review
Fisher Scientific
acrymount mounting medium
Acrymount Mounting Medium, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acrymount+mounting+medium/acrymount+mounting+medium/pmc10530398-74-0-4
Average 90 stars, based on 1 article reviews
Acrymount Mounting Medium, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/acrymount+mounting+medium/acrymount+mounting+medium/pmc10530398-74-0-4
Average 90 stars, based on 1 article reviews
acrymount mounting medium - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer"
Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
Journal: Cancer cell
doi: 10.1016/j.ccell.2023.06.010
Figure Legend Snippet:
Techniques Used: Magnetic Beads, Recombinant, Infection, Western Blot, SYBR Green Assay, Bicinchoninic Acid Protein Assay, Transfection, Purification, Gel Extraction, Cell Viability Assay, Single Cell Gel Electrophoresis, Software
Related Articles
Magnetic Beads:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. Recombinant:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. Infection:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. Western Blot:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. SYBR Green Assay:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. Bicinchoninic Acid Protein Assay:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. Transfection:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. Purification:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. Gel Extraction:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. Cell Viability Assay:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. Single Cell Gel Electrophoresis:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. Software:Article Title: Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer Article Snippet: Y , Millipore Sigma , 230251–25G. .. |